Paying users zone. Data is covered by hidden.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

Microsoft Excel LibreOffice Calc

Merck & Co. Inc. (MRK)


Statement of Cash Flows

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Merck & Co. Inc., Consolidated Statement of Cash Flows

USD $ in millions

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income hidden hidden hidden hidden hidden
Depreciation and amortization hidden hidden hidden hidden hidden
Intangible asset impairment charges hidden hidden hidden hidden hidden
Charge for future payments related to collaboration license options hidden hidden hidden hidden hidden
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation hidden hidden hidden hidden hidden
Charge related to the settlement of worldwide Keytruda patent litigation hidden hidden hidden hidden hidden
Foreign currency devaluation related to Venezuela hidden hidden hidden hidden hidden
Net charge related to the settlement of Vioxx shareholder class action litigation hidden hidden hidden hidden hidden
Gain on divestiture of Merck Consumer Care business hidden hidden hidden hidden hidden
Gain on AstraZeneca option exercise hidden hidden hidden hidden hidden
Loss on extinguishment of debt hidden hidden hidden hidden hidden
Deferred income taxes hidden hidden hidden hidden hidden
Share-based compensation hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Accounts receivable hidden hidden hidden hidden hidden
Inventories hidden hidden hidden hidden hidden
Trade accounts payable hidden hidden hidden hidden hidden
Accrued and other current liabilities hidden hidden hidden hidden hidden
Income taxes payable hidden hidden hidden hidden hidden
Noncurrent liabilities hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Net changes in assets and liabilities hidden hidden hidden hidden hidden
Adjustments to reconcile net income to net cash provided by operating activities hidden hidden hidden hidden hidden
Net cash provided by operating activities hidden hidden hidden hidden hidden
Capital expenditures hidden hidden hidden hidden hidden
Purchases of securities and other investments hidden hidden hidden hidden hidden
Proceeds from sales of securities and other investments hidden hidden hidden hidden hidden
Divestiture of Merck Consumer Care business, net of cash divested hidden hidden hidden hidden hidden
Dispositions of other businesses, net of cash divested hidden hidden hidden hidden hidden
Proceeds from AstraZeneca option exercise hidden hidden hidden hidden hidden
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired hidden hidden hidden hidden hidden
Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired hidden hidden hidden hidden hidden
Acquisitions of other businesses, net of cash acquired hidden hidden hidden hidden hidden
Acquisition of Bayer AG collaboration rights hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Net cash (used in) provided by investing activities hidden hidden hidden hidden hidden
Net change in short-term borrowings hidden hidden hidden hidden hidden
Payments on debt hidden hidden hidden hidden hidden
Proceeds from issuance of debt hidden hidden hidden hidden hidden
Purchases of treasury stock hidden hidden hidden hidden hidden
Dividends paid to stockholders hidden hidden hidden hidden hidden
Other dividends paid hidden hidden hidden hidden hidden
Proceeds from exercise of stock options hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Net cash used in financing activities hidden hidden hidden hidden hidden
Effect of exchange rate changes on cash, cash equivalents and restricted cash hidden hidden hidden hidden hidden
Net increase (decrease) in cash, cash equivalents and restricted cash hidden hidden hidden hidden hidden
Cash, cash equivalents and restricted cash at beginning of year hidden hidden hidden hidden hidden
Cash, cash equivalents and restricted cash at end of year hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-28), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-27).

Item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Merck & Co. Inc.’s net cash provided by operating activities declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Merck & Co. Inc.’s net cash (used in) provided by investing activities increased from 2016 to 2017 and from 2017 to 2018.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Merck & Co. Inc.’s net cash used in financing activities declined from 2016 to 2017 and from 2017 to 2018.